knowledge -WSS

knowledge

author：hotspot 2025-10-01 18:33:54 - browse：862

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Abortion clinic in Cancun will cater to Americans

Wikipedia

entertainment

WSS

MoonLake credibility takes another hit with mid

Excited delirium, Elijah McClain, and emergency physicians

Key House panel plots a new health care package

Sanofi seeks simpler, safer CRISPR sickle cell cure

In early work, researchers turn to CRISPR to treat Alzheimer's

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

knowledge

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Cosmetics set for new safety regulation. Why the industry is on board

Psychedelics group wrestles with new pharma identity

Startup Neumora takes a novel depression drug to Phase 3

Medicare proposal to cover medical devices draws a mixed reaction

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Activists slam private health insurers over coverage restrictions

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Psychedelics group wrestles with new pharma identity

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

entertainment

Why hospitals are withdrawing from US News rankings

Listen: Wegovy in the brain & pivotal Alzheimer's data

Startup Neumora takes a novel depression drug to Phase 3

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Medicare to cover more brain scans for Alzheimer’s patients

Startup Neumora takes a novel depression drug to Phase 3

Wikipedia

entertainment

Wikipedia

hotspot